Atypical glandular cells in Pap tests: cytology-histology correlation and risk assessment with human papillopmavirus (HPV) testing
- PMID: 38401997
- DOI: 10.1016/j.jasc.2024.01.004
Atypical glandular cells in Pap tests: cytology-histology correlation and risk assessment with human papillopmavirus (HPV) testing
Abstract
Introduction: Atypical glandular cells (AGC) represent less than 1% of Pap test cases and include a variety of lesions in both the cervix and endometrium. The study aimed to investigate the cytology-histology correlation in AGC patients and to evaluate the clinical utility of hrHPV testing in this diagnostic context.
Materials and methods: We identified 491 atypical glandular cells (AGC) cases in our quality analysis (QA) database of 336,064 Pap tests interpreted between March 1, 2013 and July 12, 2016. Of these, 251 cases had follow-up biopsies with hrHPV tests in 148 cases.
Results: The most common histologic diagnosis associated with AGC was normal/benign or low-grade lesions, comprising 55% of cervical biopsies and 24% of endometrial biopsies. High-grade lesions were identified in 21% of follow-up biopsies. In patients with AGC cytology, a positive hrHPV test significantly increased the likelihood of cervical HSIL or above lesions on biopsy by 26.4 times (OR = 26.4, 95% CI: 5.8-119.4, P < 0.0001). A positive genotyping result for HPV 16 dramatically increased the likelihood of cervical HSIL or above lesions on biopsy (OR = 84, 95% CI: 12.0-590.5, P < 0.0001). The HPV test had a negative predictive value of 97% (CI: 85%-100%).
Conclusions: Our study confirms that AGC is a significant diagnosis with an overall risk for high-grade cervical or endometrial lesions as high as 21%. hrHPV testing with genotyping is an effective tool for identifying high-risk individuals within the AGC population, with excellent positive and negative predictive values. This approach is valuable for clinical risk stratification and differential diagnosis in patients with AGC cytology.
Keywords: Adenocarcinoma; Atypical glandular cells (AGC); Cervical cancer; Human papillomavirus (HPV) test; Papanicolaou (Pap) test.
Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.
Similar articles
-
High-Risk Human Papillomavirus Testing, Genotyping, and Histopathologic Follow-up in Women With Abnormal Glandular Cells on Papanicolaou Tests.Am J Clin Pathol. 2021 Sep 8;156(4):569-576. doi: 10.1093/ajcp/aqaa265. Am J Clin Pathol. 2021. PMID: 33728437
-
Clinical utility of adjunctive high-risk human papillomavirus DNA testing in women with Papanicolaou test findings of atypical glandular cells.Arch Pathol Lab Med. 2010 Jan;134(1):103-8. doi: 10.5858/2008-0755-OAR1.1. Arch Pathol Lab Med. 2010. PMID: 20073612
-
The significance of extensive HPV genotyping for cervical high-grade neoplasia among women with atypical glandular cells.Am J Clin Pathol. 2025 Jan 28;163(1):134-142. doi: 10.1093/ajcp/aqae103. Am J Clin Pathol. 2025. PMID: 39110416
-
The utility of human papillomavirus testing in the management of atypical glandular cells on cytology.J Low Genit Tract Dis. 2009 Apr;13(2):72-8. doi: 10.1097/LGT.0b013e318183bb0e. J Low Genit Tract Dis. 2009. PMID: 19387126 Review.
-
Atypical glandular cells (AGC): Cytology of glandular lesions of the uterine cervix.Cytojournal. 2022 Apr 30;19:31. doi: 10.25259/CMAS_03_11_2021. eCollection 2022. Cytojournal. 2022. PMID: 35673694 Free PMC article. Review.
Cited by
-
Risk Assessment of Precancers and Cancers in Women with Atypical Glandular Cells of Endocervical, Endometrial, and Unknown Origin.J Cancer. 2025 Jul 11;16(10):3235-3243. doi: 10.7150/jca.111557. eCollection 2025. J Cancer. 2025. PMID: 40740227 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials